VNDA earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -1.32. Updated 2026-07-23.
Vanda Pharmaceuticals (VNDA) Research Hub
Vanda Pharmaceuticals (VNDA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.09 USD (-3.05%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.32, market cap 0.33B. This hub links to the full technical, earnings and options research available for VNDA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.09 USD (-3.05%) |
| 52-week range | 4.45 USD – 6.6 USD |
| Trend regime | Range |
| 14-day RSI | 52.3 (Neutral) |
| Trailing P/E | -1.32 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for VNDA
Covered Call on VNDA: how it works, illustrative setup around the real 5.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VNDA: how it works, illustrative setup around the real 5.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VNDA: how it works, illustrative setup around the real 5.09 USD price, max profit/loss, breakeven and when to use it. Educational.
VNDA technical analysis: range, last 5.09 USD, RSI 52.3, 52w range 4.45 USD–6.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VNDA in?
Vanda Pharmaceuticals (VNDA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VNDA in an uptrend or downtrend?
As of 2026-09-11, VNDA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VNDA's trailing P/E ratio?
VNDA's trailing P/E is -1.32, with a market cap of 0.33B. See the earnings research page for full valuation detail.
When does VNDA next report earnings?
VNDA is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.5825 USD.